PL212380B1 - [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives - Google Patents
[2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivativesInfo
- Publication number
- PL212380B1 PL212380B1 PL363979A PL36397903A PL212380B1 PL 212380 B1 PL212380 B1 PL 212380B1 PL 363979 A PL363979 A PL 363979A PL 36397903 A PL36397903 A PL 36397903A PL 212380 B1 PL212380 B1 PL 212380B1
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- derivatives
- methyl
- xantonyloxy
- acides
- Prior art date
Links
- 150000001335 aliphatic alkanes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 150000007964 xanthones Chemical class 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- -1 halogen acids Chemical class 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical class C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FXHZFKYPKHEUPL-UHFFFAOYSA-N 3-hydroxy-5-methylxanthen-9-one Chemical compound OC=1C=CC=2C(C3=CC=CC(=C3OC2C1)C)=O FXHZFKYPKHEUPL-UHFFFAOYSA-N 0.000 description 1
- JIXRMWNSKAVBJB-UHFFFAOYSA-N 6-hydroxy-2-methylxanthen-9-one Chemical compound OC1=CC=C2C(=O)C3=CC(C)=CC=C3OC2=C1 JIXRMWNSKAVBJB-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Związki o ogólnym wzorze 1 otrzymane sposobem wynalazku wykazują działanie przeciwobrzękowe i przeciwbólowe, w związku z tym mogą znaleźć zastosowanie w leczeniu stanów zapalnych (stany zwyrodnieniowe kręgosłupa, choroby reumatyczne, bóle ostre i przewlekłe).The compounds of the general formula I obtained by the method of the invention show an anti-edema and analgesic effect, therefore they can be used in the treatment of inflammatory conditions (degenerative conditions of the spine, rheumatic diseases, acute and chronic pain).
Związki 3 (Tabela 1) i 8 (Tabela 2) o ogólnym wzorze 1 można uzyskać z 4- lub 2-(metylo)-6-(hydroksy)-ksantonu (związki 1 i 7), który poddaje się reakcji O-alkilowania przy użyciu odpowiednich chlorowcokwasów w środowisku alkoholowym (metanol lub etanol) w obecności bezwodnego K2CO3 lub estrowych pochodnych chlorowcokwasów w środowisku DMF w obecności bezwodnego K2CO3, a nastę pnie alkalicznej hydrolizie surowych estrów.Compounds 3 (Table 1) and 8 (Table 2) of general formula 1 can be obtained from 4- or 2- (methyl) -6- (hydroxy) -xanthone (compounds 1 and 7) which is subjected to an O-alkylation reaction at using the appropriate halogen acids in an alcoholic medium (methanol or ethanol) in the presence of anhydrous K2CO3 or ester derivatives of halogen acids in DMF in the presence of anhydrous K2CO3, followed by alkaline hydrolysis of the crude esters.
Kwas 2-[4-(metylo)-6-ksantonylooksy]-2-metylopropanowy (związek 5, Tabela 1), uzyskuje się metodą Linka w reakcji 4-(metylo)-6-(hydroksy)-ksantonu z chloroformem i acetonem w środowisku zasadowym (NaOH). Kwasy 3, 5 (Tabela 1) i 8 (Tabela 2) scharakteryzowano poprzez odpowiednie estrowe pochodne (zw. 2, 4, 6 - Tabela 1) i 9 (Tabela 2). Wydzielony w reakcji związek 10 (Tabela 2) poprzez amonolizę w metanolowym roztworze amoniaku przekształcono dla celów badawczych w zwią zek 11 (Tabela 2).2- [4- (methyl) -6-xanthonyloxy] -2-methylpropanoic acid (compound 5, Table 1), obtained by Link's method by reacting 4- (methyl) -6- (hydroxy) -xanthone with chloroform and acetone in alkaline environment (NaOH). Acids 3, 5 (Table 1) and 8 (Table 2) are characterized by the respective ester derivatives (Comp. 2, 4, 6 - Table 1) and 9 (Table 2). Compound 10 (Table 2) isolated in the reaction was converted by ammonolysis in methanolic ammonia solution, for research purposes, into compound 11 (Table 2).
Charakterystykę związków o ogólnym wzorze 1 podano w tabeli 3.Characteristics of compounds of general formula I are given in Table 3.
Związki o ogólnym wzorze 1, zwłaszcza związki 3, 5 i 8 wykazują korzystne działanie przeciwobrzękowe i/lub przeciwbólowe. Stosowane w dawkach w zakresie 50 - 200 mg hamują narastanie obrzęku karageninowego w metodzie Wintera oraz podwyższają próg reakcji bólowej w metodzie Randalla i Selitto. Dla najaktywniejszych związków wykonano ocenę ich wpływu na błonę śluzową żołądka po jednorazowym podaniu wg metody Komatsu. Związki te wykazały zupełny brak działania ulcerogennego na śluzówką żołądka szczura, w przeciwieństwie do użytych związków odniesienia takich jak indometacyna czy ketoprofen, które silnie uszkadzały śluzówkę żołądka u badanych zwierząt. Dla porównania wyników, jako związków odniesienia, użyto aspiryny, ketoprofenu, indometacyny oraz piroksikamu. Badane związki charakteryzują się nieco niższą aktywnością przeciwobrzękową niż aspiryna, indometacyna czy ketoprofen, natomiast wykazują większą niż piroksikam aktywność przeciwbólową. Z dotychczas przebadanych struktur związki 3, 5 i 8 zakwalifikowano do poszerzonych badań farmakologicznych.The compounds of formula I, in particular compounds 3, 5 and 8, have a beneficial anti-edema and / or analgesic effect. When used in doses in the range of 50-200 mg, they inhibit the growth of carrageenan edema in the Winter method and increase the pain reaction threshold in the Randall and Selitto method. The most active compounds were assessed for their influence on the gastric mucosa after a single administration according to the Komatsu method. These compounds showed a complete lack of an ulcerogenic effect on the rat gastric mucosa, in contrast to the reference compounds used, such as indomethacin or ketoprofen, which strongly damaged the gastric mucosa in the test animals. For comparison of results, aspirin, ketoprofen, indomethacin and piroxicam were used as reference compounds. The tested compounds are characterized by a slightly lower anti-edema activity than aspirin, indomethacin or ketoprofen, while they exhibit greater analgesic activity than piroxicam. From the structures tested so far, compounds 3, 5 and 8 were qualified for extended pharmacological tests.
PL 212 380 B1PL 212 380 B1
Tabela 3. Wybrane pochodne ksantonu i dane charakterystyczneTable 3. Selected xanthon derivatives and characteristic data
PL 212 380 B1PL 212 380 B1
Tabela 3. Wybrane pochodne ksantonu i dane charakterystyczne c.d.Table 3. Selected xanthon derivatives and characteristic data continued
PL 212 380 B1PL 212 380 B1
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL363979A PL212380B1 (en) | 2003-12-10 | 2003-12-10 | [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL363979A PL212380B1 (en) | 2003-12-10 | 2003-12-10 | [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL363979A1 PL363979A1 (en) | 2005-06-13 |
| PL212380B1 true PL212380B1 (en) | 2012-09-28 |
Family
ID=35768706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL363979A PL212380B1 (en) | 2003-12-10 | 2003-12-10 | [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL212380B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL450653A1 (en) * | 2024-12-20 | 2026-06-22 | Uniwersytet Jagielloński | New xanthone derivative for use in treatment or prevention of cardiovascular diseases |
-
2003
- 2003-12-10 PL PL363979A patent/PL212380B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL363979A1 (en) | 2005-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teng et al. | Structure–activity relationship study of novel necroptosis inhibitors | |
| US6727281B2 (en) | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | |
| JP5048017B2 (en) | Substituted phenylalkanoic acid derivatives and uses thereof | |
| IL187713A (en) | 3-aminocarbazole compounds, pharmaceutical compositions containing the same and method for the preparation thereof | |
| JPH0755921B2 (en) | Amides | |
| CZ20021591A3 (en) | 5-Aryl-1H-1, 2, 4-triazoles functioning as cyclooxygenase-2y inhibitors and pharmaceutical compositions in which these compounds are comprised | |
| EP2049482B1 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate | |
| Abouzid et al. | Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives | |
| JPS61137878A (en) | 1-heteroaryl-4-aryl-pyrazolone-5-ones for drug | |
| CA2476056A1 (en) | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | |
| ITMI962385A1 (en) | PHARMACOLOGICALLY ACTIVE DIARYL-CYCLOMETHYLENPYRAZOLES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| US5288750A (en) | Substituted β-diketones | |
| ULUDAĞ et al. | Stable ester and amide conjugates of some NSAIDs as analgesic and antiinflammatory compounds with improved biological activity | |
| US20080214646A1 (en) | Novel Nsaids Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Moiety | |
| JP2011516502A (en) | Novel compounds derived from taurine, methods for their preparation and pharmaceutical compositions containing them | |
| IE882304L (en) | Naphthalenepropionic acid derivatives | |
| Li et al. | In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor | |
| JP5395905B2 (en) | Anti-inflammatory compounds | |
| Halen et al. | Substituted aminoalcohol ester analogs of indomethacin with reduced toxic effects | |
| AU2013206218A1 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate | |
| CS216206B2 (en) | Method of making the derivatives of the diphenylpyrazole | |
| CN105348169B (en) | A kind of acrylamide of inhibitors of histone deacetylase (E) 3 (2 (base of 11 hydrogen indoles of (4 chlorobenzene formacyl) 5 methoxyl group, 2 methyl 3) acetylamino) N hydroxyls fourth 2 and its preparation method and application | |
| Mo et al. | Novel 5-aminosalicylic acid NSAID conjugates: synthesis; pharmacological and toxicological properties | |
| CN105367479A (en) | Histone deacetylase inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1 hydro-indole-3-yl-N-(2-(hydroxyamino)-2-ketoacyl) acetamide and preparation method and application thereof | |
| Chandak et al. | Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20131210 |